What side effects can be expected with bevacizumab, and which are most common and bothersome to patients? What serious side effects might occur with bevacizumab?
Bevacizumab is essentially an agent that blocks VEGF. Its toxicities are mostly related to blocking VEGF, so the way I call its toxicities is that they're mostly silent toxicities. They don't manifest themselves the way they would with chemotherapy or EGFR inhibitors, meaning the patient doesn't exhibit them per se. They're limited to hypertension, and in about 12% of patients the hypertension will require medications. You would use oral hypertensives and 99% of patients would have their blood pressure controlled this way.
Issues with wound healing, so if the patient needs emergency surgery that's something to think about. If it's an elective surgery, then you just wait 4 weeks after the last dose of bevacizumab, and some prefer 6 to 8 weeks before you do the surgery, and then you start it again 4 weeks after the surgery. There's also the risk of perforation in 1% or 2% of all patients, and that risk should stop the patient from receiving bevacizumab. There is also the risk of proteinuria, or shedding proteins through the urine, but for the overwhelming majority of the patients it's not that significant.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Sotorasib/Panitumumab Combo Improves PFS in Refractory KRAS G12C+ mCRC
October 23rd 2023The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
T-IELs Could Hold the Key for CRC Immunotherapy
October 10th 2023Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
Read More
CAPOX Regimen Appears Noninferior to FOLFOX in CRC
October 8th 2023The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Read More